Kymera Therapeutics Inc
NASDAQ:KYMR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.05
94.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Kymera Therapeutics Inc
NASDAQ:KYMR
|
5.1B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.1B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.5B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Kymera Therapeutics Inc
Glance View
Kymera Therapeutics Inc., founded in 2015, is pioneering a transformative approach to drug discovery through targeted protein degradation. At its core, the company utilizes a unique technology platform, known as Pegasus, to selectively degrade disease-causing proteins. Instead of merely inhibiting proteins as traditional drugs do, Kymera's approach is to tag specific proteins for destruction by the body's own cellular machinery. This innovative strategy opens the door to treating diseases that have previously been considered "undruggable," hence expanding the horizons of therapeutic possibilities. By designing small molecules that harness the body's natural protein degradation processes, the company is strategically focused on a wide spectrum of targets, including those implicated in oncology and autoimmune diseases. Kymera's business model leverages strategic partnerships and collaborations with established pharmaceutical players to support its research and development endeavors while also transitioning several programs into the clinical phase. These collaborations not only provide crucial funding but also validate the scientific approach underpinning its technology. The company makes money through a blend of research funding, milestone payments, and potential royalty streams from partnered programs. As it builds its pipeline, Kymera remains focused on translating groundbreaking science into real-world clinical solutions, hoping to redefine how diseases are treated at their molecular roots. Through this approach, Kymera Therapeutics is not just crafting a promising business narrative but also aiming to rewrite the future of disease eradication through novel therapeutic means.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Kymera Therapeutics Inc is -750.9%, which is below its 3-year median of -396.5%.
Over the last 3 years, Kymera Therapeutics Inc’s Operating Margin has decreased from -340.8% to -750.9%. During this period, it reached a low of -750.9% on Oct 30, 2025 and a high of -204% on Jun 30, 2024.